Short Interest in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Rises By 859.7%

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 1,430,000 shares, a growth of 859.7% from the March 31st total of 149,000 shares. Based on an average daily trading volume, of 632,000 shares, the days-to-cover ratio is currently 2.3 days.

Calidi Biotherapeutics Price Performance

NYSEAMERICAN:CLDI traded up $0.00 on Thursday, hitting $0.16. The company had a trading volume of 533,100 shares, compared to its average volume of 532,412. Calidi Biotherapeutics has a 52 week low of $0.14 and a 52 week high of $13.79.

Hedge Funds Weigh In On Calidi Biotherapeutics

An institutional investor recently bought a new position in Calidi Biotherapeutics stock. Spectrum Asset Management Inc. NB CA purchased a new position in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 166,494 shares of the company’s stock, valued at approximately $94,000. Spectrum Asset Management Inc. NB CA owned 0.47% of Calidi Biotherapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on CLDI. HC Wainwright lowered their price objective on shares of Calidi Biotherapeutics from $11.00 to $2.00 and set a “buy” rating on the stock in a research note on Thursday, March 21st. Robert W. Baird decreased their price target on shares of Calidi Biotherapeutics from $9.00 to $4.50 and set an “outperform” rating on the stock in a research note on Thursday, March 21st.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.